Phenotypic and genotypic evaluation of fluoroquinolone resistance in clinical isolates of Staphylococcus aureus in Tehran

Marzieh Aligholi1, Akbar Mirsalehian1, Shahnaz Halimi1, Hossein Imaneini2, Morovat Taherikalani3, Fereshteh Jabalameli1, Parisa Asadollahi4, Babak Mohajer1, Alireza Abdollahi1, Mohammad Emaneini1

1 Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 School of ECE, College of Engineering, University of Tehran, Tehran, Iran
3 Department of Microbiology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran
4 Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

Source of support: This research was supported by Tehran University of Medical Sciences & Health Services grant 9678/30-4-88

Summary

Background: Fluoroquinolones are broad-spectrum antibiotics widely used in the treatment of bacterial infections such as Staphylococcus aureus isolates. Resistance to these antibiotics is increasing.

Material/Methods: The occurrence of mutations in the grlA and gyrA loci were evaluated in 69 fluoroquinolone-resistant S. aureus isolates from 2 teaching hospitals of Tehran University of Medical Sciences.

Results: Out of the 165 S. aureus isolates, 87 (52.7%) were resistant to methicillin and 69 (41.8%) were resistant to fluoroquinolone. Fluoroquinolone-resistant S. aureus isolates had a mutation at codon 80 in the grlA gene and different mutational combinations in the gyrA gene. These mutational combinations included 45 isolates at codons 84 and 86, 23 isolates at codons 84, 86 and 106 and 1 isolate at codons 84, 86 and 90. Fluoroquinolone-resistant S. aureus isolates were clustered into 33 PFGE types.

Conclusions: The findings of this study show that the fluoroquinolone-resistant S. aureus strains isolated in the teaching hospitals in Tehran had multiple mutations in the QRDRs region of both grlA and gyrA genes.

key words: fluoroquinolone resistance • Staphylococcus aureus • QRDR

Full-text PDF: http://www.medscimonit.com/fulltxt.php?ICID=881920

Word count: 1286
Tables: 1
Figures: 1
References: 25

Author's address: Mohammad Emaneini, Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, 100 Poursina St., Keshavarz Blvd., Tehran, Iran, e-mail: emaneini@tums.ac.ir
**BACKGROUND**

*Staphylococcus aureus*, particularly methicillin-resistant *S. aureus* (MRSA) is of great global concern as it can cause serious infections in both hospitals and the community [1–3]. Increasing resistance to antibiotics among staphylococcal isolates limits the choices of antibiotics available to treat infections caused by these bacteria [4]. Fluoroquinolones are broad-spectrum antibiotics widely used in the treatment of bacterial infections such as gram-positive cocci; however, resistance to these antibiotics has significantly increased worldwide [5,6]. Three different mechanisms of fluoroquinolones resistance have been described in staphylococci. The first is the mutation in the *grlA* and *grlB* genes that encodes the subunits of DNA topoisomerase IV, the second is the mutation in the *gyrA* and *gyrB* genes that encode the subunits of DNA gyrase, and the third is an active efflux pump mediated by mutations in the *norA* gene [5–9]. In most cases, mutations occur in the highly conserved quinolone resistance-determining regions (QRDRs) of the *grlA* and *gyrA* genes [10].

Despite the high incidence of fluoroquinolones resistance among staphylococci, especially among MRSA, there is currently little information available on the incidence and the types of these resistances in many countries. This lack of information is of particular concern in the Persian Gulf region, where the prevalence of MRSA is high [9,11]. The aim of the present study was to provide information regarding the prevalence of fluoroquinolones resistance among *S. aureus* isolates in Tehran, Iran.

**MATERIAL AND METHODS**

**Bacterial strains**

A total of 165 *S. aureus* clinical isolates were cultured from patients attending 2 teaching hospitals of Tehran University of Medical Sciences between April 2009 and September 2010 (155 isolates from Imam Khomeini hospital and 10 isolates from Amir Alam hospital). They were cultured from wounds, blood, CSF, body fluid, and urine. Only 1 isolate per patient was included. Isolates were identified to species level using standard biochemical methods including Gram stain, catalase test, tube coagulase, DNase, and fermentation of mannitol [12,13].

**Antimicrobial susceptibility test**

Antibiotic-containing disks (Mast, UK) were used to determine the susceptibility of *S. aureus* isolates to several antibiotics according to the criteria established by the Clinical and Laboratory Standards Institute (CLSI) [14]. The antibiotics tested were ciprofloxacin, gatifloxacin, levofloxacin, norfloxacin, ofloxacin, and oxacillin. The minimum inhibitory concentrations (MIC) of ciprofloxacin, ofloxacin and oxacillin were determined using the microbroth dilution method as recommended by the CLSI guidelines. *S. aureus* (ATCC 29213) was used as control.

**Amplification of mecA, grlA, and gyrA genes**

Chromosomal DNA was extracted from the clinical *S. aureus* isolate as previously described [2]. The *mecA*, *grlA*, and *gyrA* genes were amplified by PCR-based methods, using specific primers [10,15,16]. PCR reactions were performed in a 50 µL volume consisting of 1X PCR buffer, 3 mM MgCl₂, 0.4 µg/mL of each primer, 1.5 U *Taq* DNA polymerase, 0.2 mM dNTP Mix and 5 µL of DNA template. The PCR conditions consisted of a pre-denaturation step at 94°C for 5 min, followed by 30 cycles of at 94°C for 40 sec, 51°C for 40 sec and 72°C for 45 sec. A final extension step was performed at 72°C for 5 min. To determine the QRDRs sequences, the PCR products of *grlA* and *gyrA* genes were sequenced with both forward and reverse strands at Macrogen (Seoul, South Korea). Sequences were compared with wild-type sequences of *grlA* and *gyrA* genes with no mutations [17].

**Pulsed Field Gel Electrophoresis (PFGE)**

All fluoroquinolone-resistant *S. aureus* isolates were analyzed by PFGE. The entire genomic DNA was prepared as described previously [15]. After digestion with *SmaI* endonuclease, DNAs were separated by PFGE (APZoha, Tehran, Iran) for 24 h at 15°C, with an electric field of 6 V/cm² in 0.5x TBE buffer. The pulse time increased from 1 to 30 sec for 11 h and 1 to 3 sec for 13 h. The gels were stained with ethidium bromide (1 µg/ml) and visualized by UV illumination. DNA from *S. aureus* NCTC8325 was prepared in the same way and run as molecular size standard.

**RESULTS**

*S. aureus* strains were isolated from wounds (76), blood (42), respiratory tract (20), joint fluid (15), urine (11) and CSF (1) in this study.

Out of the 165 *S. aureus* isolates, 87 (52.7%) and 69 (41.8%) were resistant to methicillin and tested fluoroquinolone antibiotics, respectively. All MRSA isolates contained *mecA* gene and 67 (77%) isolates were resistant to fluoroquinolones. Overall, the oxacillin MIC₉₀ and MIC₅₀ levels among isolates of MRSA were 128 µg/ml and 512 µg/ml, respectively.

The results of mutations in the QRDRs of the *gyrA* and *grlA* genes and the MIC of ciprofloxacin and ofloxacin among fluoroquinolone-resistant *S. aureus* isolates examined in this study are shown in Table 1. In all the assessed isolates, a mutation in the *grlA* gene was observed at codon 80. Fluoroquinolone-resistant *S. aureus* isolates had different combinations of mutations in the *gyrA* gene. These mutations included 45 isolates at codons 84 and 86, 23 isolates at codons 84, 86 and 106, and 1 isolate at codons 84, 86 and 90.

Among the 69 fluoroquinolone-resistant *S. aureus* isolates, 42 PFGE patterns were generated by digestion with *SmaI*, which clustered into 33 PFGE types. The majority of the isolates (52) were clustered in 16 pulsotypes (Figure 1), and 4 PFGE types displayed subtypes. Seventeen PFGE types contained a single isolate.

**DISCUSSION**

The spread of antimicrobial resistance among *S. aureus* isolates is a worldwide problem. Since fluoroquinolones, particularly ciprofloxacin and gatifloxacin, are widely used in Iran to treat a variety of infections such as staphyloccal...
The high prevalence rate of MRSA (52.7%) in the present study is alarming and indicates an increase in the prevalence rate reported in Tehran teaching hospitals in 2008 was 36% [15]. This finding highlights the importance of modified empiric therapy and infection control policies among hospitals in Iran.

The results of this study show a fluoroquinolone resistance rate of 41.8% among S. aureus isolates, which was higher than the 13% to 20.7% reported by similar investigations [5,16,24]. Many studies have shown that 1 or 2 point mutations in the QRDRs region of both grlA and gyrA genes are the main mechanisms of fluoroquinolone resistance, in particular ciprofloxacin resistance, among S. aureus isolates [6,16,21,22]. In agreement with many other studies, the results showed that all the fluoroquinolone-resistant isolates had a single mutation at codon 80 in the grlA gene and a mutation at codons 84 in the gyrA gene [16,17,23]. Among the 69 tested isolates, 23 had an additional mutation at codon 106 and 1 had a mutation at codon 90 in the gyrA gene. The mutation at codon 106 has also been reported in a few studies, but its effect on resistance was reported to be unknown [17,21]. According to our literature review, the point mutation at codon 90 (Tyr to Ser) in the gyrA gene has not been reported previously and further studies are needed to determine its effect on fluoroquinolone resistance. In the current study, all the fluoroquinolone-resistant isolates had a mutation at codon 86 in the gyrA gene; this point mutation is a silent mutation and has already been reported by others [8,24].

Our results are consistent with those of others who found that the same mutations in the QRDRs were detected in different PFGE types, and different combinations of mutations were also found in the isolates of the same PFGE type [10,16,25].

**Conclusions**

In conclusion, our findings show that fluoroquinolone-resistant S. aureus strains isolated from teaching hospitals in Tehran have multiple mutations in the QRDRs region of both grlA and gyrA genes.

**References:**

1. Brumfitt W, Hamilton-Miller JM: The worldwide problem of methicillin-resistant Staphylococcus aureus. Drugs Exp Clin Res, 1990; 16: 205–14
2. Emaneini M, Taherikalani M, Eslampour MA et al: Phenotypic and genotypic evaluation of aminoglycoside resistance in clinical isolates of staphylococci in Tehran, Iran. Microb Drug Resist, 2009; 15: 129–32
3. Nicholas BD, Bhargave G, Hatipoglu A et al: Preoperative prevalence of methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients undergoing intranasal surgery. Med Sci Monit, 2010; 16(8): CR565–68
4. Chambers HF: Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. Clin Microbiol Rev, 1997; 10: 781–91
5. Hooper DC: Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect Dis, 2002; 2: 530–38
6. Schmitz FJ, Higgins PG, Mayer S et al: Activity of quinolones against gram-positive cocci: mechanisms of drug action and bacterial resistance. Eur J Clin Microbiol Infect Dis, 2002; 21: 647–59
7. Horii T, Suzuki Y, Takeshita A, Maekawa M: Molecular characterization of 8-methoxyfluoroquinolone resistance in a clinical isolate of methicillin-resistant Staphylococcus aureus. Chemotherapy, 2007; 53: 104–9
8. Tanaka M, Wang T, Onodera Y et al: Mechanism of quinolone resistance in Staphylococcus aureus. J Infect Chemother, 2000; 6: 151–39
9. Tanaka M, Onodera Y, Uchida Y, Sato K: Quinolone resistance mutations in the GrlB protein of Staphylococcus aureus. Antimicrob Agents Chemother, 1998; 42: 3044–46

---

**Table 1. Mutations in grlA and gyrA genes and susceptibilities in fluoroquinolone resistant Staphylococcus aureus isolates.**

| Gene | codon | Mutation | No of isolates | MIC of CIP* (μg/ml) | MIC of OFX (μg/ml) |
|------|-------|----------|----------------|---------------------|-------------------|
|      |       |          |                | Range 50% 90%       | Range 50% 90%     |
| grlA | 80    | TCC→TTC  | 69             | 16–128 16 128       | 8–32 8 32         |
|      | 84 + 86 | TCA→TAA + ATT→ATC | 45 | 16–64 16 32 | 8–32 8 16 |
|      | 84 + 86 + 90 | TCA→TAA + ATT→ATC + ATG→AGG | 1 | 16 16 16 | 8 8 8 |
|      | 84 + 86 + 106 | TCA→TAA + ATT→ATC + GGC→GAC | 23 | 16–128 32 | 128 8–32 16 32 |

* MIC – Minimum Inhibitory Concentration; CIP – ciprofloxacin; OFX – ofloxacin.
10. Iihara H, Suzuki T, Kawamura Y et al: Emerging multiple mutations and high-level fluoroquinolone resistance in methicillin-resistant *Staphylococcus aureus* isolated from ocular infections. Diagn Microbiol Infect Dis, 2006; 56: 297–303

11. Fatholahzadeh B, Emaneini M, Gilbert G et al: Staphylococcal cassette chromosome mec (SCCmec) analysis and antimicrobial susceptibility patterns of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates in Tehran, Iran. Microb Drug Resist, 2008; 14: 217–20

12. Mahon CR, Lehman DC, Manuselis G: Text book of diagnostic microbiology. 3rd ed. Philadelphia, PA, USA 2007

13. Reissner SB, Woods GL, Thomson RP et al: Specimen collection. In: Murray PR, Baron EJ, Pfaller MA et al., (eds.), Manual of clinical microbiology (7th ed.), American Society for Microbiology, Washington, DC, 64–76, 1999

14. Clinical and Laboratory Standards Institute: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational Supplement. 2011; 31: M100-S21.

15. Fatholahzadeh B, Emaneini M, Aligholi M et al: Molecular characterization of methicillin-resistant *Staphylococcus aureus* clones from a teaching hospital in Tehran. Jpn J Infect Dis, 2009; 62: 309–11

16. Horii T, Suzuki Y, Monji A et al: Detection of mutations in quinolone resistance-determining regions in levofloxacin- and methicillin-resistant *Staphylococcus aureus*: effects of the mutations on fluoroquinolone MICs. Diagn Microbiol Infect Dis, 2003; 46: 139–45

17. Schmitz FJ, Jones ME, Hofmann B et al: Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of *Staphylococcus aureus* and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother, 1998; 42: 1249–52

18. Emaneini M, Aligholi M, Hashemi FB et al: Isolation of vancomycin-resistant *Staphylococcus aureus* in a teaching hospital in Tehran. J Hosp Infect, 2007; 66: 92–93

19. Blumberg HM, Rimland D, Carroll DJ et al: Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant *Staphylococcus aureus*. J Infect Dis, 1991; 163: 1279–85

20. Marango FB, Miller D, Mualllem MS et al: Ciprofloxacin and levofloxacin resistance among methicillin-sensitive. *Staphylococcus aureus* isolates from keratitis and conjunctivitis. Am J Ophthalmol, 2004; 137: 453–58

21. Coskun-Ari FF, Bogenlmez-Tinaz G. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin-methicillin-resistant *Staphylococcus aureus*. Eur J Med Res, 2008; 13: 566–70

22. Takahata M, Yonezawa M, Kurose S et al: Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant *Staphylococcus aureus*. J Antimicrob Chemother, 1996; 38: 543–46

23. Yoon EJ, Lee CY, Shim MJ et al: Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant *Staphylococcus aureus*. Chemotherapy, 2010; 56: 153–57

24. Wang T, Tanaka M, Sato K. Detection of grlA and gyrA mutations in 344 *Staphylococcus aureus* strains. Antimicrob Agents Chemother, 1998; 42: 2396–40

25. Noguchi N, Okihara T, Namiki Y et al: Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant *Staphylococcus aureus* isolated in 2002. Int J Antimicrob Agents, 2005; 25: 374–79